TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mucociliary transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Change in Bone Resorption: NTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Bone Formation: BAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sensitivity/specificity for colorectal cancer (CRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline-corrected QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of vaccinees with virus-neutralizing antibodies ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-hepatitis A Virus (HAV) Seropositivity Status at 8 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-hepatitis A Virus (HAV) Seropositivity Status at 10 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptance of Remote Patient Monitoring Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breath gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall response rate (RECIST CRITERIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone Mineral Density (t-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with Relapse at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Relapse at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Financial well being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance on the paired associate recall test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with renal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MGRSS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time until initiation of therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of tooth sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in postoperative emergence agitation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Safety and tolerability of PF-04360365
Endpoint domain: Adverse events/effects
Primary endpoint: Change in urinary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in International Index of Erectile Function [IIEF] score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in FIQL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Female Sexual Function Index [FSFI]
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peri-implantitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean osseointegration period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ARFI velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Serum CD 20 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Small Intestine Histology Based on Villous Height to Crypt Depth (Vh:Cd) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Small Intestine Histology Based on Intraepithelial Lymphocytes (IEL) Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kappa Statistic for Correlation of Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurence of gastroesophageal reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportion of patients with PCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal sensation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery Slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of those who report a combined outcome of presence of anxiety or depression at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of who report a combined outcome of either presence of anxiety or depression from baseline to the end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of those who report signs and symptoms or evidence consistent with probable diagnosis of COVID-19 from baseline to the end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in auditory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level Dependent (BOLD) Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ecological Momentary Assessment (EMA) Pleasure Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Actigraphy derived sleep parameters
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of hospital acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy against malaria sporozoite challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Doses Received of HPV Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PSA Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Objective Response Rate (ORR) by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tau positive scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Acute energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time until first composite CV event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aberrant Behavior Checklist-irritability subscale (ABC-I)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sedation level classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of HBsAg positivity in infants at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemical remission (serum levels of ASAT and ALAT within normal ranges)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of steroid specific side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Regrowing Tumor Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State-Trait Anxiety Scale (STAI TX-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Saliva Cortisol Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum caspofungin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Centers for Disease Control (CDC) and Prevention Health-Related Quality of Life Scale (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Centers for Epidemiological Studies Depression Scale (CESD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual instability symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve from 0 to time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Overall Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Treatment Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended Phase 2 Dose (RP2D) of LAM561
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Maternal Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very Good Partial Response Rate or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour urine sodium/potassium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of Formative Evaluation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Rate of Seven-Day Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival status at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Safety of freeze-dried rabies vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of procedural complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patient-reported symptoms related to procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Arthritis Impact Measurement Scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical radiologic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of RT-PCR test conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: duration of MRI-HIFU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UFS-Qol
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of 5 mmHg SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of 10 mmHg SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Triglycerides blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: spinal canal stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sagittal alignment of vertebral column
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertebral body compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: type of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Scoring for density of hair regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoring of overall response at the end of the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin level variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of HBsAg disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to Viral Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Drug-Related Serious Adverse Event (SAE) During the Long-Term Follow-Up
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Anti-HBs Antibody Concentrations Above Cut Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk for hepatocellular carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in episodes of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SNOT-22 Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ΔAUCGLP-1-OGTT(0-240)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need of Exchange Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Somatization symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for Completion of Tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in Detecting the Tips of Tubes, Lines, and Wires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digestive prevalence rate of 3GCREB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: venous fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in transverse neck rhytides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Measure bio-markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of urinary hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of blood hemojuvelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endothelial glycocalyx integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Threshold Audiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 day-all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvements in ASIA Impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvements in Somatosensory Evoked Potentials (SSEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvements in Motor Evoked Potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Step length assessment while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma GnRH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma TRH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma CRH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma somatostatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physical Activity Minutes Per Week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diabetes self-care activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oxygen supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy failure (treated biopsy-proven acute rejection, graft loss, death, or loss to follow-up)
Endpoint domain: Mortality/survival
Primary endpoint: thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: progression of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: in vitro basophil activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Patients With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline at Week 54 in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline at Week 54 in Pulse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: POC INR and PTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PK measures of blood anatabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6 minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Systolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change of 4 TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour measurements of 5 indicator skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants That Experience Progression by 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in pneumococcal serotype-specific IgG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean 24-hour pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing Parkinson's disease
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction/Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hot Flash Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in volume of overinflated lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Leukemia risk
Endpoint domain: Mortality/survival
Primary endpoint: Rectus femoris length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Biceps femoris strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gluteus maximus strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Who Experience Venous Thromboembolism Events (VTE) or Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Photoplethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colonic Transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic accuracy of biomarkers for MCI due to AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC last (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC total (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Cognition and Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Disease prognosis outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-cell Function - C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sedation Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average Mean Numeric Pain Rating Scale (NPRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence rates of oesophageal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rates of stomach cancer
Endpoint domain: Mortality/survival
Primary endpoint: Eradication of multi-drug resistant bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Identification of biomarkers for ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Healing of nonunions and fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes